Stockscreener 앱 받기
1.185
22.18%
0.211
Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide - Investing.com
MIRA Expands Global Ketamir-2 License for Clinical Development - TipRanks
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide By Investing.com - Investing.com Canada
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) expands Ketamir-2 license to worldwide IP rights - Stock Titan
Experimental oral chemo nerve damage drug gets IP boost in 10 countries - Stock Titan
MIRA Stock Price, Quote & Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals (MIRA) Q3 2025 Earnings: Why the Beat MattersRising Community Picks - Newser
MIRA Stock Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
What's going on with MIRA Pharma stock Tuesday? - MSN
Should You Sell MIRA Pharmaceuticals (MIRA) After -1.24% Drop? 2026-05-15Golden Cross - Newser
MIRA Pharmaceuticals (MIRA) Delivers Q3 2025 Beat — EPS $-0.06 vs $-0.08 ExpectedAnalyst Stock Picks - Newser
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 - Investing.com UK
Mira Pharmaceuticals stock gains on Phase 1 trial results By Investing.com - Investing.com South Africa
Mira Pharmaceuticals stock gains on Phase 1 trial results - Investing.com
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 By Investing.com - Investing.com Canada
Chemo nerve damage has no FDA drugs—MIRA advances new Ketamir-2 pill - Stock Titan
MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results - TipRanks
MIRA (MIRA) posts positive Phase 1 data and DEA decision on Ketamir-2 - Stock Titan
MIRA Pharmaceuticals Announces Publication of Preclinical Data on SKNY-1 for Obesity and Nicotine Addiction in International Journal of Molecular Sciences 8910 - Minichart
Mira Pharmaceuticals announces peer-reviewed publication of SKNY-1 preclinical data - Investing.com Nigeria
MIRA publishes preclinical study on obesity drug candidate SKNY-1 By Investing.com - Investing.com South Africa
MIRA publishes preclinical study on obesity drug candidate SKNY-1 - Investing.com
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate - ACCESS Newswire
MIRA highlights SKNY-1 preclinical data in new publication - TipRanks
Fish study: MIRA test pill cuts weight 30% and dampens nicotine-seeking - Stock Titan
MIRA Pharmaceuticals publishes preclinical SKNY-1 study showing weight loss, lipid benefits - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) highlights SKNY-1 preclinical obesity and nicotine data - Stock Titan
Is MIRA Pharmaceuticals (MIRA) stock hiding in plain sight? (Wavering) 2026-05-11Crowd Entry Points - Newser
Number of shareholders of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) Top Loser | Q3 2025: Profit SurprisesPost Earnings - UBND thành phố Hải Phòng
Should I buy MIRA Pharmaceuticals (MIRA) stock right now | Q3 2025: EPS Exceeds ExpectationsMargin of Safety - UBND thành phố Hải Phòng
MIRA Pharmaceuticals (MIRA) Stock: Momentum Analysis (Momentum Building) 2026-04-16Low Volatility Stocks - Xã Vĩnh Công
0.12%
0.06%
자본화:
|
볼륨(24시간):